These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29718334)

  • 21. Association of NAFLD With Diabetes and the Impact of BMI Changes: A 5-Year Cohort Study Based on 18,507 Elderly.
    Liu M; Wang J; Zeng J; Cao X; He Y
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1309-1316. PubMed ID: 28324002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
    Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
    Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy.
    Wong VW; Wong GL; Yeung DK; Lau TK; Chan CK; Chim AM; Abrigo JM; Chan RS; Woo J; Tse YK; Chu WC; Chan HL
    J Hepatol; 2015 Jan; 62(1):182-9. PubMed ID: 25195550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes.
    Bril F; Kadiyala S; Portillo Sanchez P; Sunny NE; Biernacki D; Maximos M; Kalavalapalli S; Lomonaco R; Suman A; Cusi K
    J Investig Med; 2016 Jan; 64(1):63-8. PubMed ID: 26755815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes.
    Shanaki M; Moradi N; Emamgholipour S; Fadaei R; Poustchi H
    Diabetes Metab Syndr; 2017 Nov; 11 Suppl 1():S467-S472. PubMed ID: 28392354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic.
    Dvorak K; Hainer R; Petrtyl J; Zeman M; Vareka T; Zak A; Sroubkova R; Svestka T; Vitek L; Bruha R
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):442-8. PubMed ID: 25004910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
    Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R;
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
    Patoulias D
    Acta Medica (Hradec Kralove); 2017; 60(4):167-170. PubMed ID: 29716685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes.
    Yamazaki H; Tsuboya T; Tsuji K; Dohke M; Maguchi H
    Diabetes Care; 2015 Sep; 38(9):1673-9. PubMed ID: 26156527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial.
    Zhang HJ; He J; Pan LL; Ma ZM; Han CK; Chen CS; Chen Z; Han HW; Chen S; Sun Q; Zhang JF; Li ZB; Yang SY; Li XJ; Li XY
    JAMA Intern Med; 2016 Aug; 176(8):1074-82. PubMed ID: 27379904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus.
    Olusanya TO; Lesi OA; Adeyomoye AA; Fasanmade OA
    Pan Afr Med J; 2016; 24():20. PubMed ID: 27583084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-Alcoholic Fatty Liver Disease Is a Risk Factor for the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus.
    Jia G; Di F; Wang Q; Shao J; Gao L; Wang L; Li Q; Li N
    PLoS One; 2015; 10(11):e0142808. PubMed ID: 26566287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
    Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
    Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention and treatment effect of total flavonoids in Stellera chamaejasme L. on nonalcoholic fatty liver in rats.
    Wang Y; Li JY; Han M; Wang WL; Li YZ
    Lipids Health Dis; 2015 Aug; 14():85. PubMed ID: 26242978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.